“We are thrilled with Pat’s contribution to our investment team. He hit the ground running, and he has been a key contributor to a couple of our investments already. The firm continues to focus on internal development and promotion from within as we build Riverside Partners,” said David Belluck, General Partner.
Prior to joining Riverside he was a vice president at Bain Capital where he worked in the private equity group evaluating transactions across a range of industries, geographies, and company sizes. Prior to Bain Capital, he worked at consulting firm Bain & Company. He has a BA in International Relations from Stanford and an MBA from Harvard. Mr. Dooling serves on the boards of Loftware and R&D Altanova.
Riverside has been a very active investor of late. Yesterday, the firm announced the closing of two transactions: the acquisition of a majority equity interest in Bottom Line Systems, a provider of revenue cycle management technology and services to large hospital systems and other healthcare providers; and the add-on acquisition by BioAgilytix of IPM Biotech, a German-based bioanalytical contract research laboratory.
Riverside Partners invests in middle market healthcare and technology-oriented companies that have revenues from $20 million to $200 million and EBITDA’s from $5 million to $25 million. The firm is currently investing its fifth fund, Riverside Partners Fund V, LP, with $561 million of capital commitments. Riverside was founded in 1989 and is based in Boston (www.riversidepartners.com).
© 2016 Private Equity Professional • Private Equity’s Leading News Magazine • 3-22-16